
Easy to Use
In a survey conducted with over 100 doctors and nurses, 94% found the device easier to use than a regular needle
In a survey conducted with over 100 doctors and nurses, 94% found the device easier to use than a regular needle

Virtually Pain- and Bruise-Free
Less painful and less traumatic than a conventional needle, supporting better comfort and higher patient adherence
Less painful and less traumatic than a conventional needle, supporting better comfort and higher patient adherence

Shallow
Histological studies have confirmed that injected materials are defined well within the dermis with low variability
Histological studies have confirmed that injected materials are defined well within the dermis with low variability


Consistent
Blebs of >6 mm (which is the key for successful intradermal injection) were observed in 98% of the injections, evaluated in over 1,200 injections in more than 860 subjects in several clinical studies
Blebs of >6 mm (which is the key for successful intradermal injection) were observed in 98% of the injections, evaluated in over 1,200 injections in more than 860 subjects in several clinical studies

Applicable to All Ages
-Pediatrics applicability, as demonstrated by large Phase III study on 6-week-old infants1
-Elderly applicability was demonstrated in several clinical study2,3
-Pediatrics applicability, as demonstrated by large Phase III study on 6-week-old infants1
-Elderly applicability was demonstrated in several clinical study2,3

Commercially Available
The MicronJet™ is available commercially in numerous territories including the US, EU, Brazil, China and Korea and is used for potential applications such as BCG vaccination, tuberculin skin test and allergy testing.
The MicronJet™ is available commercially in numerous territories including the US, EU, Brazil, China and Korea and is used for potential applications such as BCG vaccination, tuberculin skin test and allergy testing.
1 Anand A, Zaman K, Estívariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine. 2015;33(48):6816-6822. doi:10.1016/j.vaccine.2015.09.039
2 Della Cioppa G, Nicolay U, Lindert K, et al. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Hum Vaccin Immunother. 2014;10(6):1701-1710. doi:10.4161/hv.28618
3 Hung IF, Levin Y, To KK, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012;30(45):6427-6435. doi:10.1016/j.vaccine.2012.08.014
2 Della Cioppa G, Nicolay U, Lindert K, et al. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Hum Vaccin Immunother. 2014;10(6):1701-1710. doi:10.4161/hv.28618
3 Hung IF, Levin Y, To KK, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012;30(45):6427-6435. doi:10.1016/j.vaccine.2012.08.014
